Gilead Sciences (GILD) EBT Margin (2009 - 2026)
Gilead Sciences (GILD) reported EBT Margin of 37.07% for Q1 2026, up 1234.0% on a YoY basis from 2.78% in Q1 2025, and up 41.37% quarter-over-quarter from 26.22% in Q4 2025.
Gilead Sciences (GILD) EBT Margin (2009 - 2026) Analysis & Trends
Gilead Sciences has reported EBT Margin for 18 years, with the latest figure at 37.07% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin rose 1234.0% year-over-year to 37.07%; the trailing twelve-month figure through Mar 2026 stood at 36.08% (up 1233.0% YoY), and the FY2025 full-year result was 33.27%, up 3087.0% from the prior year.
- EBT Margin for Q1 2026 stood at 37.07%, up from 26.22% in the prior quarter.
- The five-year high for EBT Margin was 46.87% in Q3 2025, with the low at 67.1% in Q1 2024.
- Historically, EBT Margin has averaged 21.02% across 5 years, with a median of 26.22% in 2025.
- Annual changes were most pronounced in 2024 — EBT Margin plunged 8756 bps — and 2025, when it surged 9183 bps.
- Gilead Sciences' EBT Margin stood at 27.49% in 2022, then decreased by 15 bps to 23.24% in 2023, then advanced by 23 bps to 28.63% in 2024, then dropped by 8 bps to 26.22% in 2025, then surged by 41 bps to 37.07% in 2026.
- The last three EBT Margin figures came in at 37.07% (Q1 2026), 26.22% (Q4 2025), and 46.87% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 28.10% |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 44.70% |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 24.89% |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 6.93% |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -21.49% |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 24.18% |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 37.07% |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 135.53% |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 28.20% |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.07% |
| Dec 31, 2025 | 26.22% |
| Sep 30, 2025 | 46.87% |
| Jun 30, 2025 | 34.30% |
| Mar 31, 2025 | 24.73% |
| Dec 31, 2024 | 28.63% |
| Sep 30, 2024 | 12.67% |
| Jun 30, 2024 | 29.52% |
| Mar 31, 2024 | -67.10% |
| Dec 31, 2023 | 23.24% |
| Sep 30, 2023 | 32.87% |
| Jun 30, 2023 | 24.06% |
| Mar 31, 2023 | 20.47% |
| Dec 31, 2022 | 27.49% |
| Sep 30, 2022 | 34.54% |
| Jun 30, 2022 | 24.01% |
| Mar 31, 2022 | -2.31% |
| Dec 31, 2021 | 10.48% |
| Sep 30, 2021 | 46.33% |
| Jun 30, 2021 | 29.23% |